Ameriprise Financial Inc. Grows Stake in Altimmune, Inc. (NASDAQ:ALT)

Ameriprise Financial Inc. grew its stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 35.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,254,898 shares of the company's stock after buying an additional 1,378,854 shares during the period. Ameriprise Financial Inc. owned 7.39% of Altimmune worth $37,888,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in ALT. SBI Securities Co. Ltd. acquired a new stake in Altimmune in the fourth quarter valued at approximately $45,000. Virtus ETF Advisers LLC acquired a new stake in Altimmune in the fourth quarter valued at approximately $60,000. Cullen Frost Bankers Inc. acquired a new stake in Altimmune in the fourth quarter valued at approximately $72,000. 180 Wealth Advisors LLC acquired a new stake in Altimmune in the fourth quarter valued at approximately $78,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Altimmune in the fourth quarter valued at approximately $81,000. Institutional investors and hedge funds own 78.05% of the company's stock.

Insider Buying and Selling

In other news, CFO Gregory L. Weaver purchased 10,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were purchased at an average cost of $5.20 per share, with a total value of $52,000.00. Following the acquisition, the chief financial officer now directly owns 10,000 shares of the company's stock, valued at $52,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on ALT. HC Wainwright reissued a "buy" rating and issued a $12.00 price objective on shares of Altimmune in a research note on Thursday, April 3rd. William Blair reiterated a "market perform" rating on shares of Altimmune in a report on Friday, March 14th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $20.20.

Altimmune Stock Down 3.5%

Shares of NASDAQ ALT traded down $0.20 during midday trading on Friday, reaching $5.58. The company had a trading volume of 2,112,290 shares, compared to its average volume of 2,828,491. The firm's fifty day moving average price is $5.11 and its 200-day moving average price is $6.56. The stock has a market cap of $429.74 million, a PE ratio of -3.60 and a beta of 1.13. Altimmune, Inc. has a one year low of $3.55 and a one year high of $11.16.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.09. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. During the same quarter in the prior year, the business earned ($0.34) EPS. As a group, equities research analysts expect that Altimmune, Inc. will post -1.35 EPS for the current year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.